The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Abstract
Purpose: To determine the antitumor activity of the novel proteasome inhibitor bortezomib in patients with indolent and mantle-cell lymphoma (MCL). Patients and Methods: Patients with indolent and MCL were eligible. Bortezomib was given at a dose of 1.5 mg/m 2 on days 1, 4, 8, and 11. Patients were required to have received no more than three prior chemotherapy regimens, with at least 1 month since the prior treatment, 3 months from prior rituximab, and 7 days from prior corticosteroids; absolute neutrophil count more than 1,500/μL (500/μL if documented bone marrow involvement); and platelet count more than 50,000/μL. Results: Twenty-six patients were registered, of whom 24 were assessable. Ten patients had follicular lymphoma, 11 had MCL, three had small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL), and two had marginal zone lymphoma. The overall response rate was 58%, with one complete remission (CR), one unconfirmed CR (CRu), and four partial remissions (PR) among patients with follicular non-Hodgkin's lymphoma (NHL). All responses were durable, lasting from 3 to 24+ months. One patient with MCL achieved a CRu, four achieved a PR, and four had stable disease. One patient with MCL maintained his remission for 19 months. Both patients with marginal zone lymphoma achieved PR lasting 8+ and 11+ months, respectively. Patients with SLL or CLL have yet to respond. Overall, the drug was well tolerated, with only one grade 4 toxicity (hyponatremia). The most common grade 3 toxicities were lymphopenia (n = 14) and thrombocytopenia (n = 7). Conclusion: These data suggest that bortezomib was well tolerated and has significant single-agent activity in patients with certain subtypes of NHL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
An Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death
Beg, A. A., & Baltimore, D. (1996) · Science · doi:10.1126/science.274.5288.782 · Cited by 3,047
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationPalombella, V. J., Rando, O. J., Goldberg, A. L., & Maniatis, T. (1994) · Cell · doi:10.1016/s0092-8674(94)90482-0 · Cited by 2,096
Cheson, B., Bennett, J., Grever, M., Kay, N., Keating, M., O'Brien, S., & Rai, K. (1996) · Blood · doi:10.1182/blood.v87.12.4990.bloodjournal87124990 · Cited by 1,819
Hideshima, T., Richardson, P. G. G., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., & Anderson, K. C. (2001) · PubMed · Cited by 1,508
Self-citationHow Proteolysis Drives the Cell Cycle
King, R. W., Deshaies, R. J., Peters, J.-M., & Kirschner, M. W. (1996) · Science · doi:10.1126/science.274.5293.1652 · Cited by 1,273
Davis, R. E., Brown, K. D., Siebenlist, U., & Staudt, L. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.12.1861 · Cited by 1,051
Orlowski, R. Z., Stinchcombe, T. E., Mitchell, B. S., Shea, T. C., Baldwin, A. S., Stahl, S., Adams, J., Esseltine, D.-L., Elliott, P. J., Pien, C. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.133 · Cited by 760
Self-citationPotent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
Adams, J., Behnke, M., Chen, S., Cruickshank, A. A., Dick, L. R., Grenier, L., Klunder, J. M., Ma, Y.-T., Plamondon, L., & Stein, R. L. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00029-8 · Cited by 685
Self-citationMantle Cell Lymphoma: A Clinicopathologic Study of 80 Cases
Argatoff, L. H., Connors, J. M., Klasa, R. J., Horsman, D. E., & Gascoyne, R. D. (1997) · Blood · doi:10.1182/blood.v89.6.2067 · Cited by 497
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.
Aghajanian, C. A., Soignet, S. L., Dizon, D. S., Pien, C. S., Adams, J., Elliott, P. J., Sabbatini, P. J., Miller, V. A., Hensley, M. L., Pezzulli, S., et al. (2002) · PubMed · Cited by 447
Self-citationRead, M. A., Neish, A. S., Luscinskas, F. W., Palombella, V. J., Maniatis, T., & Collins, T. (1995) · Immunity · doi:10.1016/1074-7613(95)90030-6 · Cited by 347
An, B., Goldfarb, R. H., Siman, R., & Dou, Q. P. (1998) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400436 · Cited by 337
Pham, L. V., Tamayo, A. T., Yoshimura, L. C., Lo, P., & Ford, R. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.1.88 · Cited by 320
Adhesion molecules in tumor metastasis.
Zetter, B. R. (1993) · PubMed · Cited by 318
Ling, Y. H., Liebes, L., Jiang, J. D., Holland, J. F., Elliott, P. J., Adams, J., Muggia, F. M., & Perez-Soler, R. (2003) · PubMed · Cited by 257
Self-citationProteasome Inhibition: a New Strategy in Cancer Treatment
Adams, J., Palombella, V. J., & Elliott, P. J. (2000) · Investigational New Drugs · doi:10.1023/a:1006321828515 · Cited by 248
Self-citationChiarle, R., Budel, L. M., Skolnik, J., Frizzera, G., Chilosi, M., Corato, A., Pizzolo, G., Magidson, J., Montagnoli, A., Pagano, M., et al. (2000) · Blood · doi:10.1182/blood.v95.2.619 · Cited by 216
Chemosensitization of Pancreatic Cancer by Inhibition of the 26S Proteasome
Bold, R. J., Virudachalam, S., & McConkey, D. J. (2001) · Journal of Surgical Research · doi:10.1006/jsre.2001.6194 · Cited by 212
Ling, Y. H., Liebes, L., Ng, B., Buckley, M. T., Elliott, P. J., Adams, J., Jiang, J. D., Muggia, F. M., & Perez-Soler, R. (2002) · PubMed · Cited by 205
Self-citationFrankel, A., Man, S., Elliott, P. J., Adams, J., & Kerbel, R. S. (2000) · PubMed · Cited by 201
Self-citationDelic, J., Masdehors, P., Ömura, S., Cosset, J.-M., Dumont, J., Binet, J.-L., & Magdelénat, H. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.183 · Cited by 195
Marshansky, V. N., Wang, X., Bertrand, R., Luo, H., Duguid, W. P., Chinnadurai, G., Kanaan, N., Vu, M. D., & Wu, J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.5.3130 · Cited by 120
Harousseau, J., Shaughnessy, J. D., & Richardson, P. G. G. (2004) · Hematology · doi:10.1182/asheducation-2004.1.237 · Cited by 106
Ohshima, K., Muta, H., Kawasaki, C., Muta, K., Deyev, V. V., Kanda, M., Kumano, Y., Podack, E. R., & Kikuchi, M. (2001) · International Journal of Oncology · doi:10.3892/ijo.19.2.283 · Cited by 24
Vega, F., & Medeiros, L. J. (2001) · Advances in Anatomic Pathology · doi:10.1097/00125480-200111000-00001 · Cited by 21
Cited by
Proteasome inhibitors in cancer therapy
Manasanch, E. E., & Orlowski, R. Z. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.206 · Cited by 1,024
Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Chen, D., Frezza, M., Schmitt, S., Kanwar, J., & P. Dou, Q. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911794519752 · Cited by 795
Mutant p53 as a guardian of the cancer cell
Mantovani, F., Collavin, L., & Del Sal, G. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0246-9 · Cited by 775
Kuhn, D. J., Chen, Q., Voorhees, P. M., Strader, J. S., Shenk, K. D., Sun, C. M., Demo, S. D., Bennett, M. K., van Leeuwen, F. W. B., Chanan-Khan, A. A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065888 · Cited by 768
Fisher, R. I., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9665 · Cited by 704
Self-citation
Metadata
- Authors
- O'Connor, O. A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli, B., Stubblefield, M., Straus, D., Portlock, C., Hamlin, P., Choi, E., Dumetrescu, O., Esseltine, D., Trehu, E., Adams, J., Schenkein, D., & Zelenetz, A. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-02-01
- Volume
- 23
- Issue
- 4
- Pages
- 676-684
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2100608938
- Cited by
- 577
- References
- 29
- FWCI
- 32.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.